10-methoxy-6,8-dihydro-5H-isoquinolino[2,1-b]isoquinoline-2,3,9-triol | 1018809-17-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: 10-methoxy-6,8-dihydro-5H-isoquinolino[2,1-b]isoquinoline-2,3,9-triol
• CAS: 1018809-17-0
• 化学式: C₁₈H₁₇NO₄
• 分子量: 311.337
• InChiKey: UGRLCVKANRKFJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  73.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  小檗红碱 在 间苯三酚 、 硫酸 、 水 作用下， 反应 1.0h， 以31%的产率得到10-methoxy-6,8-dihydro-5H-isoquinolino[2,1-b]isoquinoline-2,3,9-triol
  参考文献：
  名称：

  13,13A-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE

  摘要：

  公开号：

  EP2070926B1

文献信息

• 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2070926A1

  公开（公告）日：2009-06-17

  The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.

  本发明提供了由下式表示的13,13a-二氢小檗碱衍生物或其生理上可接受的盐、由其组成的药物组合物及其用途。13,13a-二氢小檗碱衍生物具有促进肌肉细胞吸收葡萄糖的活性，整体动物试验表明，本发明化合物具有改善糖耐量和胰岛素抵抗、促进减肥、缓解脂肪肝等作用。因此，本化合物可用于治疗胰岛素抵抗引起的糖尿病、肥胖症、脂肪肝及其并发症。
• 13,13a-Dihydroberberine Derivatives For Use In Pharmaceutical Compositions
  申请人：Hu Lihong

  公开号：US20100113494A1

  公开（公告）日：2010-05-06

  The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.
• 13,13A-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2070926B1

  公开（公告）日：2011-09-07